Development Considerations of Antifungal Drugs to Address Unmet Medical Need — August 4, 2020

Speakers and Panelists: Affiliations and Disclosures

David Angulo, MD
Chief Medical Officer
Scynexis, Inc.
Jersey City, NJ

John Bennett, MD
Senior Investigator
Clinical Mycology Section
NIAID, NIH
Bethesda, MD

Radu Botgros, MD
Scientific Officer
Office of Biological Health Threats and Vaccines Strategy
European Medicines Agency (EMA)
Amsterdam, the Netherlands

Helen Boucher, MD
Chief, Division of Geographic Medicine and Infectious Diseases
Director, Tufts Center for Integrated Management of Antimicrobial Resistance (CIMAR)
Director, Heart Transplant and Ventricular Assist Device Infectious Diseases Program
Professor of Medicine
Division of Geographic Medicine and Infectious Diseases
Tufts Medical Center
Boston, MA

Tom M. Chiller, MD
Chief, Mycotic Diseases Branch
Associate Director of Global Programs
Division of Foodborne, Waterborne, and Environmental Diseases
Nation Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA

Philip Colangelo, Pharm.D., PhD
Clinical Pharmacology Team Leader,
Division of Clinical Pharmacology IV
OTS, CDER, FDA
Silver Spring, MD
Aaron Dane, MSc
Director
DaneStat Consulting Limited
Macclesfield, United Kingdom

David Denning
Professor of Infectious Diseases in Global Health
The University of Manchester
Manchester, UK

Cheryl Dixon, PhD
Statistical Reviewer
Division of Biometrics IV (DBIV), Office of Translational Sciences (OTS)
CDER, FDA
Silver Spring, MD

Dennis Dixon, PhD
Chief, Bacteriology and Mycology Branch
National Institute of Allergy and Infectious Diseases (NIAID), NIH
Bethesda, MD

John Farley, MD, MPH
Director
Office of Infectious Diseases (OID)
OND, CDER, FDA
Silver Spring, MD

Karen Higgins, Sc.D.
Statistical Team Leader
DBIV, OTS
OND, CDER, FDA
Silver Spring, MD

Michael R. Hodges, MD, BSc.
Chief Medical Officer
Amplyx Pharmaceuticals, Inc.,
San Diego, CA

William Hope, Ph.D.
Dame Sally Davies Chair of AMR Research
Director, Centre of Excellence in Infectious Diseases Research
Department of Molecular and Clinical Pharmacology
University of Liverpool
United Kingdom
Caroline Jjingo, MD, MPH  
Clinical Reviewer  
Division of Anti-Infectives (DAI), Office of Infectious Diseases (OID)  
OND, CDER, FDA  
Silver Spring, MD

Aspasia Katragkou, MD, PhD  
ESPID Fellow, Transplantation-Oncology Infectious Disease Program  
Weill Cornell Medicine  
New York, New York

Laura Kovanda, Ph.D.  
Senior Director, Global Development Project Leader  
Astellas Pharma Global Development, Inc.  
Northbrook, IL

Baoying Liu, MD, PhD  
Program Officer  
NIAID, NIH  
Rockville, MD

Shawn Lockhart, Ph.D.  
Senior Clinical Laboratory Advisor  
Senior Advisor for AMR  
Mycotic Diseases Branch  
Centers for Disease Control and Prevention  
Atlanta, GA

Johan Maertens, MD  
Associate Professor of Hematology  
University Hospital  
Leuven  
Belgium

Kieren Marr, MD, MBA  
Professor of Medicine  
Vice Chair of Medicine for Innovation in Healthcare Implementation  
Director of Transplant and Oncology Infectious Diseases  
Johns Hopkins University School of Medicine  
Baltimore, MD
Jason Moore, Pharm.D.
Clinical Pharmacology Reviewer
Division of Infectious Disease Pharmacology (DIDP)
Office of Clinical Pharmacology (OCP)
FDA/CDER/OTS
Silver Spring, MD

Sumathi Nambiar, MD, MPH
Director
DAI, OID
OND, CDER, FDA
Silver Spring, MD

Elizabeth O’Shaughnessy, MD
Clinical Reviewer
DAI, OID
OND, CDER, FDA
Silver Spring, MD

Luis Ostrosky-Zeichner, MD
Vice-Chair of Medicine
Director of the Laboratory of Mycology Research
McGovern Medical School
Houston, TX

Peter Pappas, MD
Professor of Medicine
Medicine/Infectious Diseases Department
University of Alabama
Birmingham, AL

Thomas Patterson, MD
Vice-Chair for Faculty Development
Chief, Division of Infectious Diseases
Professor of Medicine
Director, San Antonio Center for Medical Mycology
The University of Texas Health Science Center at San Antonio
San Antonio TX

John Perfect, MD
Professor of Medicine
James B. Duke Distinguished Professor of Medicine
Chief, Division of Infectious Diseases
Professor in Molecular Genetics and Microbiology
Durham, NC
John Rex, MD  
Chief Medical Officer & Director  
F2G, Ltd  
Manchester, UK

Taylor Sandison, MD, MPH  
Chief Medical Officer  
Cidara Therapeutics  
San Diego, CA

Matthew Schueler  
Founder  
Henry Schueler Foundation  
Chicago, IL

George Thompson, MD  
Associate Professor of Medicine  
Department of Medicine, Division of Infectious Diseases  
Department of Medical Microbiology and Immunology  
UC-Davis Medical Center

Thomas Walsh, MD, PhD  
Founding Director, Transplantation-Oncology Infectious Diseases Program  
Chief, Infectious Diseases Translational Research Laboratory  
Professor of Medicine, Pediatrics, and Microbiology & Immunology  
Weill Cornell Medicine of Cornell University and New York Presbyterian Hospital  
Henry Schueler Foundation Scholar  
Investigator of Emerging Infectious Diseases of the Save Our Sick Kids Foundation  
New York, NY

Yuliya Yasinskaya, MD  
Clinical Team Leader  
DAI, OID  
OND, CDER, FDA  
Silver Spring, MD

Erin Zeituni, PhD  
Preclinical Services Program Manager  
Bacteriology and Mycology Branch  
Division of Microbiology and Infectious Diseases  
NIAID, NIH  
Bethesda, MD
Lanling Zou, MD, PhD  
Bacteriology Program Officer  
Chief, Translational Sciences Section  
Bacteriology and Mycology Branch  
Division of Microbiology and Infectious Diseases  
NIAID, NIH  
Bethesda, MD

**Disclosures**

**David Angulo** is an employee of SCYNEXIS, Inc.

**Helen Boucher** is the editor of ID Clinics of North America, Antimicrobial Agents and Chemotherapy, and the Sanford Guide; Treasurer of the Infectious Diseases Society of America, and Voting Member of the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCRB), and retiree from the ID Board of the American Board of Internal Medicine.

**Aaron Dane** of DaneStat Consulting is a statistical consultant for the Pharmaceutical and Biotechnology Industry. He has acted as a consultant for Achaogen, Allecra, Amicrobe, Amplyx, Artizan, Cidara, ContraFect, Davolterra, Destiny, F2G, Geom, GSK, Gyroscope, Kymab, Mironid, Modis, Nabriva, Orca, Pfizer, Phico, Pled, Roche, Scynexis, Spero, TenNor, Transcrip, VenatoRx and Zavante.

**David Denning** and family hold Founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company. He acts or has recently acted as a consultant to Scynexis, Pulmatrix, Pulmocide, Zambon, iCo Therapeutics, Mayne Pharma, Biosergen, and Fujifilm. In the last 3 years, he has been paid for talks on behalf of Hikma, Gilead, Merck, Mylan and Pfizer. He is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group.

**William Hope** is (or has been) a consultant to F2G, Amplyx, Pfizer and Gilead.

**Laura Kovanda** is a full-time employee of Pharma Company Astellas Pharma Global Development, Inc.

**Kieren Marr** is founder and CEO of MycoMed Technologies. Consultant and Advisory Board member for Cidara Therapeutics and Sfunga Therapeutics. She has consulted for Amplyx Pharmaceuticals, Astellas Pharma, Advaxis, Chimerix, F2G Ltd, Genentech, Incyte Corp, Merck & Co., OncoSec, RTI Surgical, Scynexis, Inc. and Vical. She receives authorship and editorial royalties from UpToDate and a grant from Merck.
John Rex is Chief Medical Officer & Director, F2G, Ltd.; Operating Partner & Consultant, Advent Life Sciences; and Expert-in-Residence, Wellcome Trust; He sits on the scientific advisory boards of Bugworks Research, Inc.; Basilea Pharmaceutica; Forge Therapeutics, Inc.; Novo Holdings; and Roche Pharma Research & Early Development; He is a shareholder in AstraZeneca Pharmaceuticals; F2G, Ltd; Advent Life Sciences; Macrolide Pharmaceuticals; and Bugworks Research, Inc.; He has received consulting fees from Phico Therapeutics; ABAC Therapeutics; Polyphor, Ltd.; Heptares Therapeutics, Ltd.; Gangagen, Ltd.; Meiji Seika Pharma; Basilea Pharmaceutica International Ltd.; Allecra Therapeutics GmbH; Forge Therapeutics, Inc.; SinSa Labs; AtoxBio; Peptilogics; F. Hoffmann-LaRoche, Ltd.; Novo Holdings; Innocoll; Vedanta; Progenity; Nosopharm SA; Roivant Sciences; and Shionogi Inc.

Luis Ostrosky-Zeichner has received research funding and/or personal honoraria for consulting or speaking from Pfizer, Merck, Astellas, Cidara, Scynexis, F2G, Amplyx, Gilead, Therapeutics, Inc, Viracor, Octapharma, Biotoscana, Stendhal, Mayne, Takeda, RealTime labs, and Viracor.

Thomas Patterson has received research grants to UT Health San Antonio from Cidara and F2G and has served as a consultant for Basilea, Gilead, Mayne, Merck, Pfizer, Scynexis, Sfunga, & Toyama.

Taylor Sandison is a full-time employee of Cidara Therapeutics.


Thomas Walsh has received grants for experimental and clinical antimicrobial pharmacology and therapeutics to his institution from Allergan, Amplyx, Astellas, Lediant, Medicines Company, Merck, Scynexis, and Tetraphase and has served as consultant to Amplyx, Astellas, Allergan, ContraFect, Gilead, Leadiant, Medicines Company, Merck, Methylgene, Pfizer, and Scynexis.